Our findings suggest that RIPK1 activity can protract disease and RIPK1 antagonism may be therapeutically relevant for improving hematopoiesis and long-term outcomes in patients surviving acute, severe infections where type I IFNs are elevated. This evidence concerns the gene RIPK1 and infection.